These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33272531)

  • 1. Texture analysis applied in T1 maps and extracellular volume obtained using cardiac MRI in the diagnosis of hypertrophic cardiomyopathy and hypertensive heart disease compared with normal controls.
    Shi RY; Wu R; An DL; Chen BH; Wu CW; Du L; Jiang M; Xu JR; Wu LM
    Clin Radiol; 2021 Mar; 76(3):236.e9-236.e19. PubMed ID: 33272531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiomic Analysis of Myocardial Native T
    Neisius U; El-Rewaidy H; Nakamori S; Rodriguez J; Manning WJ; Nezafat R
    JACC Cardiovasc Imaging; 2019 Oct; 12(10):1946-1954. PubMed ID: 30660549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease.
    Liang L; Wang X; Yu Y; Zhang Y; Liu J; Chen M; Zhang L; Jiang T
    Int J Gen Med; 2022; 15():4163-4173. PubMed ID: 35465304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texture analysis and machine learning of non-contrast T1-weighted MR images in patients with hypertrophic cardiomyopathy-Preliminary results.
    Baeßler B; Mannil M; Maintz D; Alkadhi H; Manka R
    Eur J Radiol; 2018 May; 102():61-67. PubMed ID: 29685546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy.
    Neisius U; Myerson L; Fahmy AS; Nakamori S; El-Rewaidy H; Joshi G; Duan C; Manning WJ; Nezafat R
    PLoS One; 2019; 14(8):e0221061. PubMed ID: 31433823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients.
    Yue X; Yang L; Wang R; Chan Q; Yang Y; Wu X; Ruan X; Zhang Z; Wei Y; Wang F
    Front Cardiovasc Med; 2022; 9():1017097. PubMed ID: 36330005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1 mapping in children and young adults with hypertrophic cardiomyopathy.
    Parekh K; Markl M; Deng J; de Freitas RA; Rigsby CK
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):109-117. PubMed ID: 27659477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cellular and extracellular pathology assessed by T1 mapping on regional contractile function in hypertrophic cardiomyopathy.
    Swoboda PP; McDiarmid AK; Erhayiem B; Law GR; Garg P; Broadbent DA; Ripley DP; Musa TA; Dobson LE; Foley JR; Fent GJ; Page SP; Greenwood JP; Plein S
    J Cardiovasc Magn Reson; 2017 Feb; 19(1):16. PubMed ID: 28215181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial fibrosis evaluated by diffusion-weighted imaging and its relationship to 3D contractile function in patients with hypertrophic cardiomyopathy.
    Wu R; An DA; Shi RY; Chen BH; Jiang M; Bacyinski A; Han TT; Hu J; Xu JR; Wu LM
    J Magn Reson Imaging; 2018 Oct; 48(4):1139-1146. PubMed ID: 29601139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping.
    Wu LM; An DL; Yao QY; Ou YZ; Lu Q; Jiang M; Xu JR
    Clin Radiol; 2017 Oct; 72(10):835-843. PubMed ID: 28552325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive marker for evaluation of hypertensive heart disease: extracellular volume and myocardial strain.
    Niu J; Zeng M; Wang Y; Liu J; Li H; Wang S; Zhou X; Wang J; Li Y; Hou F; Zhu J
    BMC Cardiovasc Disord; 2020 Jun; 20(1):292. PubMed ID: 32539749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncontrast T1ρ dispersion imaging is sensitive to diffuse fibrosis: A cardiovascular magnetic resonance study at 3T in hypertrophic cardiomyopathy.
    Wang K; Zhang W; Li S; Jin H; Jin Y; Wang L; Li R; Yang Y; Zheng J; Cheng J
    Magn Reson Imaging; 2022 Sep; 91():1-8. PubMed ID: 35525524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between myocardial hypoxia and fibrosis in hypertrophic cardiomyopathy: analysis by T2* BOLD and T1 mapping MRI.
    Ando K; Nagao M; Watanabe E; Sakai A; Suzuki A; Nakao R; Ishizaki U; Sakai S; Hagiwara N
    Eur Radiol; 2020 Aug; 30(8):4327-4336. PubMed ID: 32211964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial extracellular volume fraction measurements with MOLLI 5(3)3 by cardiovascular MRI for the discrimination of healthy volunteers from dilated and hypertrophic cardiomyopathy patients.
    Cui Y; Chen Y; Cao Y; Liu J; Song J; Zhang S; Kong X; Han P; Shi H
    Clin Radiol; 2019 Sep; 74(9):732.e9-732.e16. PubMed ID: 31122714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.
    Hinojar R; Varma N; Child N; Goodman B; Jabbour A; Yu CY; Gebker R; Doltra A; Kelle S; Khan S; Rogers T; Arroyo Ucar E; Cummins C; Carr-White G; Nagel E; Puntmann VO
    Circ Cardiovasc Imaging; 2015 Dec; 8(12):. PubMed ID: 26659373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotyping of hypertensive heart disease and hypertrophic cardiomyopathy using personalized 3D modelling and cardiac cine MRI.
    Chuah SH; Md Sari NA; Chew BT; Tan LK; Chiam YK; Chan BT; Lim E; Abdul Aziz YF; Liew YM
    Phys Med; 2020 Oct; 78():137-149. PubMed ID: 33007738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis.
    Korthals D; Chatzantonis G; Bietenbeck M; Meier C; Stalling P; Yilmaz A
    Sci Rep; 2021 Jul; 11(1):15521. PubMed ID: 34330967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.